The health services industry is also showing some bright spots. The Danish company Novo Nordisk (NVO), specializing in diabetes care and hormone therapy, has been performing very well since mid-November of last year and is up over 16 percent year-to-date. With a cap of $85.93 billion, sales at $13.75 billion, and forward P/E ratio of $23.27, analysts are rating NVO right now as a strong buy, and this is reflected in its current share price of $192.69 (up over 25 percent since last November).
Celldex Therapeutics (CLDX) is another such example, up 10.5 percent this year. According to their website, CLDX is “the first anti-body based combination Immunotherapy Company” that specializes in cancer and other difficult-to-treat medical conditions. Sporting relatively more modest cap and sales figures ($459.89 million and $10 million respectively), their stock price has climbed rather quickly to $7.68 since last November when it was at $5. While the company is still too young to have any reliable projections figures, the nature of their work and the fact that they are also being rated as a Strong Buy are facts that suggest they should by all means be kept on the radar.
Finally, Delek Logistics Partners LP (DKL), a new U.S.-based independent oil and gas company that owns pipeline, transportation, and marketing assets, has put up a strong performance with an over 13 percent gain year-to-date. Its cap is currently at $625.44 million, while sales are at $960.37 million, and its share price has climbed rather quickly to $26.47. Add to that a forward P/E of 17.14 percent, and an EPS for the next year projected at 78.82 percent, this company is another one to keep an eye on throughout 2013.